Isomorphic Labs, an AI drug development startup, is in financing discussions with a valuation of at least 40 billion USD

Alphabet's AI drug development company Isomorphic Labs, led by Demis Hassabis, is in early negotiations for a new round of financing, with a valuation of at least $40 billion, potentially reaching $50 billion.

The company completed a $2.1 billion Series B financing in May this year. Reports also indicate that the application of AI in the biopharmaceutical field is still in its early stages, and more efforts are needed before clinical trials and product launches. This negotiation is still in the early stages, and specific terms and investor information have not been disclosed.